You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

Article metrics

Article menu

Download PDFPDF

Spondyloarthritis
Original research
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

AbstractFullPdf
Mar 2022321320124
Apr 202213713352
May 202211611343
Jun 2022938934
Jul 2022898545
Aug 2022949021
Sep 2022767754
Oct 2022817723
Nov 2022494724
Dec 2022656325
Jan 2023636324
Feb 2023828326
Mar 2023272418
Apr 2023232119
May 2023383627
Jun 2023363621
Jul 2023262516
Aug 2023141411
Sep 2023333215
Oct 2023383424
Nov 2023252419
Dec 2023363617
Jan 2024453719
Feb 2024343221
Mar 2024333172
Total16741622794